## COVID-19 Clinical Risk Assessment Tool Data Protection Impact Assessment (DPIA)

## Version 1.0 (template) 16 February 2021

**Compliance with General Data Protection Regulation (GDPR)**

The COVID-19 Clinical Risk Assessment Tool, powered by QCovid®, (the Tool) does not capture and store personal data about the patient. NHS Digital, who host the Tool, is therefore not processing any personal data about patients in providing the Tool. Clinicians, however, will be processing personal data about a patient when they use the Tool, as part of a clinical consultation with the patient and otherwise to support direct care of patients. In particular, if the results from the risk assessment are recorded into the patient’s health record, this will be processing personal data about the patient in their health record.

The organisations determine their purposes and means of the processing of personal data and are therefore controllers under UK General Data Protection Regulation (GDPR) in relation to the patient data processed by clinicians through using the Tool and recording the risk assessment results. To support organisations using the COVID-19 Clinical Risk Assessment Tool, NHS Digital has produced this Data Protection Impact Assessment (DPIA) template. A template patient Privacy Notice has also been provided, which can be shared with patients who may wish to know more information about the Tool and the risk assessment results recorded in their health record.

# Controller details

|  |  |
| --- | --- |
| Name of controller | Westcroft house Surgery |
| Name of controller contact /DPO | Dr Celia Heasman |

# Step 1: Identify the need for a DPIA

|  |
| --- |
|  |
| **Project Aims**  The project will allow trained clinicians from a healthcare organisation to use the Tool which is an online tool made available to the healthcare organisation to enable shared decision making for direct care purposes. The COVID-19 Clinical Risk Assessment Tool estimates the risks of patients catching coronavirus and being admitted to hospital  and catching coronavirus and dying from coronavirus (COVID-19), which can be used to produce a coronavirus risk assessment results for a patient. The Tool is based on risk factors, such as: age, gender, ethnic group, health conditions and current medications.  The risk assessment results are used by clinicians to help their patients to understand their risk and discuss actions that could be taken in the context of other important factors including occurrences of coronavirus in the local area, risk appetite, occupation and personal circumstances. Clinical conversations could include advice to shield to limit the risks of catching the virus, ways in which health can be improved (such as losing weight) to reduce the risk of serious illness if infected, and coronavirus risk mitigation (refer to clinical guidance). The Tool may also be used by the clinician in preparation for a consultation or otherwise for direct care purposes including to help them in considering whether their patient should be included on the Shielded Patient List (SPL). Using the Tool to assist the clinician in considering adding or removing a patient to/from the SPL should only be done in accordance with the clinical guidance on use of the Tool provided.  The Tool is provided by NHS Digital as instructed by the Department of Health and Social Care to support health interventions in relation to coronavirus.  **Types of processing**  The following types of processing occur:   * Collection of personal data from the patient and from the healthcare organisation’s patient records, to input into the Tool; * Through the Tool profiling the data input to derive risk assessment results in relation to coronavirus for the patient; * Discussing the risk assessment results with their patient in context of providing direct care to their patient; * Recording the fact that coronavirus risk assessment results has been obtained and/or the results on the patient’s record. * Otherwise used by the clinician to provide direct care to their patient including whether they should be included on the SPL. This should only be done in accordance with clinical guidance on use of the Tool provided.   The Tool itself does not process personal data.  **Need for DPIA**  The need for a DPIA arises because the healthcare organisation shall be undertaking the following in relation to personal data in obtaining coronavirus risk assessment results from the Tool:   1. Evaluation or scoring; 2. Processing of sensitive personal data or data of a highly personal nature; 3. Processing of data concerning vulnerable data subjects; 4. Innovative technological or organisational solutions; and 5. Profiling, including of health, ethnicity and other characteristics.   **Limitations**  The Tool generates risk assessment results based upon the level of risk from coronavirus arising to the patient for the purposes of clinical consultation with the patient, in preparation for a consultation with a patient or for other direct care purposes.  The underlying model for the Tool is based upon coronavirus experience during wave 1 (spring 2020) of the pandemic and the risk to patients of coronavirus may, in some circumstances, be different. In particular:   1. Shielding, social distancing measures and coronavirus infection prevalence may be different now; 2. Certain health conditions may not have been identified as representing particular coronavirus related risks in the Tool but may arise subsequently; and 3. The widespread availability of coronavirus testing.   The Tool shall be updated as knowledge of coronavirus risks matures. |

# Step 2: Describe the processing

|  |
| --- |
|  |
| The healthcare organisation will collect the personal data:   1. Directly from the patient, in a clinical consultation, with the patient or for the purposes of direct patient care; 2. From patient records held by the healthcare organisation, for the purposes of direct patient care;   The healthcare organisation will use the personal data as follows:   1. Personal data is not inputted into the Tool. Characteristics obtained from the patient and/or from their healthcare records are inputted into the Tool, but they do not identify the patient. The only potentially identifiable data input is the postcode which is immediately converted into a non-identifiable social deprivation number, which feeds into the risk assessment results generated by the Tool. 2. Discuss the risk assessment results with the patient in context of a direct care healthcare conversation between the clinician and the patient;   The healthcare organisation will record and store the personal data as follows:-   1. Record the fact that a coronavirus risk assessment has been obtained, the version number of the Tool and/or the risk assessment results on the patient’s record. 2. The healthcare organisation may also record other personal data provided by the patient or obtained in the consultation where appropriate to update the patient record 3. No personal data is stored on the Tool or NHS Digital platforms.   The healthcare organisation consider that the processing is likely to be high risk (as defined in GDPR) for the following reasons:   1. While the Tool itself does not process personal data, the use of it by the clinician means that the healthcare organisation is processing personal data including special category data (as defined by Article 9 of UK GDPR) because we can identify the patient who is in consultation with the clinician. The high risk processing being undertaken by the health organisation includes:    * Evaluation or scoring (by virtue of the risk assessment results);    * Processing of sensitive personal data or data of a highly personal nature (through collection and assessment, and discussion with the patient);    * Processing of data concerning vulnerable data subjects (as some data subjects will be elderly, have learning difficulties, mental health needs and other vulnerabilities);    * Innovative technological or organisational solutions (by virtue of the Tool);    * Profiling, including of health, ethnicity and other characteristics (through delivering risk assessment results).   Please refer to the health organisation’s full Privacy Notice for details of where they may onwardly share personal data. |

|  |
| --- |
|  |
| The clinician enters the following key risk characteristics of the patient into the Tool to assess coronavirus risk as part of a consultation with a patient:   * + - Age (over 19 and under 100)     - Sex registered at birth     - Ethnicity     - Living arrangements (whether you live in your own home, in a care home or are homeless)     - Postcode. Leave blank if unknown. Postcode is used to determine the level of social deprivation in the patient’s area of residence using the Townsend score     - Height (cm), Weight (Kg) – used to calculate BMI     - Cardiovascular diseases     - Respiratory diseases and treatment     - Metabolic, renal and liver conditions     - Neurological and psychiatric conditions     - Autoimmune and haematological conditions     - Cancer and immunosuppressants – If you have a diagnosis of certain cancers and you have been prescribed if you have been prescribed 4 or more times with certain immunosuppressants in the last 6 months.   Ethnic group and health condition information would consist of special category data.  It may be necessary to process wider information about a patient’s health for the purposes of understanding and inputting the patient’s key characteristics (as set out above) into the Tool.  The Tool does not provide any functionality to record or upload the risk assessment results onto a patient’s record. If the clinician chooses to record the use of the Tool or the risk assessment results themselves on a patient record, the healthcare organisation will become the Controller for that information as well as the information it collects and processes during a consultation with a patient, including the clinician’s input into the Tool.  Any personal data retained on the patient record shall be retained in accordance with the healthcare organisation’s data retention policy, which should be detailed on the organisation’s privacy notice to patients.  No personal data is processed by the Tool itself.  Please refer to the healthcare organisation’s full Privacy Notice for details of data retention and location of data. |

|  |
| --- |
|  |
| **The nature of our relationship with individuals**  The Tool is used by the patient’s clinician in discussion with the patient in a direct care setting, during a consultation with a patient and otherwise to support direct care of patients.  **The patient’s control over the processing**  The clinician will use the COVID-19 Clinical Risk Assessment Tool to assess the patient’s risks in relation to coronavirus to support the direct care of the patient. The clinician provides advice and guidance to the patient.  **Would patients expect their data to be used in this way?**  The Tool is used only in a direct care setting or otherwise for direct care purposes for the patient. A patient privacy notice is also supplied and can be provided to patients. The proposed processing would therefore be within their expectations.  **Does the processing include children or other vulnerable groups?**  The Tool should only be used for adults aged 19 and over. Processing will include the processing of data concerning vulnerable individuals (as some individuals will be elderly, have learning difficulties, mental health needs and other vulnerabilities).  **Are there prior concerns over this type of processing or security flaws?**  There should be no processing of personal data outside of the normal personal data systems of the healthcare organisation. The Tool does not itself process personal data and therefore presents no differentiated data security risk.  The use of the Tool by the clinician is profiling of the patient, including ethnicity and health condition categories in an automated way. Profiling is therefore considered in more detail in this DPIA but it is noted it takes place in the context of clinical direct care consultations with patients, or otherwise for direct care purposes which does not in itself raise any unusual concerns. Although the Tool processes data in an automated way to produce risk assessment results, this does not result in any automated decision. The clinician should always use the Tool in accordance with the clinical guidance provided within the Tool.  **Is it novel in any way?**  This is a newly developed Tool for assessing coronavirus risk, to enable a consultation between a patient and their clinician to consider their risk from coronavirus and for other related direct care purposes for the patient. The Tool has been certified as a class 1 medical device by the Medicines and Healthcare products Regulatory Agency (MHRA) and carries the CE mark. Class 1 contains medical devices that have a low to moderate risk to the patient or user. The CE mark is a logo that indicates the Tool meets legislation relating to safety and performance  **What is the current state of technology in this area?**  This is a newly developed Tool for assessing coronavirus risk, to enable a consultation between a patient and their clinician to consider their risk to coronavirus and otherwise for direct care purposes for the patient.  **Are there any current issues of public concern that you should factor in?**  The Tool uses a risk prediction model which has been developed on the basis of research into key risk factors in relation to the coronavirus outbreak. As this is an ongoing pandemic, the clinical risk factors shall evolve as more research and evidence becomes available.  A potential public concern could be that the Tool results in automated decision making from automated processing, including profiling, of personal data. However, the Tool itself does not process personal data. In the context in which the Tool is used by the clinician, the only application of the Tool is direct care of the patient through a patient/clinician consultation with the patient and otherwise for the purposes of direct care. This would not amount to automated decision making because no decisions are taken based solely on the risk assessment results which are being used for the purposes of clinical consultation and direct care purposes only. The clinical guidance on use of the Tool makes clear it is not to be used to make decisions but can be used to assist the clinician in making a decision. Additionally, there is human intervention from the clinician in relation to how the results may then be subsequently used, including any decision to record them into the patient’s medical record.  In addition, in relation to patients who have conditions that would have led them to be identified as clinically extremely vulnerable and who would be advised to shield during the first few months of the pandemic, the Tool may currently underestimate their risk of coronavirus. Clinical guidance on use of the Tool makes clear that clinicians should use it with clinical judgement to help them as the clinician in advising the patient and otherwise in support of the healthcare needs of the patient.  **Are you signed up to any approved code of conduct or certification scheme (once any have been approved)?**  No. |

|  |
| --- |
|  |
| The personal data input by a clinician into the Tool will be processed to generate individual coronavirus risk assessment results for the patient, detailed in Step 4 below.  This enables an informed conversation between the medically trained professional and their patient about the nature and extent of their health risks in relation to coronavirus infection. The outcome for patients is that their clinician may gain a better understanding of their risks of infection and potential consequences for them of infection with coronavirus and the clinician is better able to advise the patient of their risks through a clinical consultation. This may include advice on shielding, weight management and other health and lifestyle considerations.  Anonymous data will be collected by NHS Digital through the Tool. This anonymous data may be shared with Oxford University, who developed the risk prediction model which the Tool uses and the Department of Health and Social Care to develop and improve the risk prediction model and the Tool. |

# Step 3: Consultation process

|  |
| --- |
|  |
| NHS Digital has consulted and/or been provided with advice by:   * Department of Health and Social Care * Chief Medical Officer and Deputy Chief Medical Officer (CMO) * NHS England and NHS Improvement * Public Health England * Oxford University * Internal teams within NHS Digital e.g. Shielded Patient List team * An expert advisory group consisting of Information Commissioners Office (ICO), National Data Guardian (NDG) and NHS Digitals Information Group Advising on Release of Data (IGARD) members, as critical friends * NHS X Vaccinations Programme * NHS Digital Caldicott Guardian * Professional and membership bodies in health, including RCGP, RCP and BMA * Patient groups and health charities |

# Step 4: Assess necessity and proportionality

|  |
| --- |
|  |
| **Does the processing actually achieve your purpose?**  The Tool is expected to enable the clinician to have a deeper and more clinically effective consultation with patients about the coronavirus risk that applies personally to them. It is also expected to increase the clinician’s understanding of the risks to their patient of coronavirus which may help in their direct care for that patient. This is because the Tool is derived from research carried out by Oxford University based upon coronavirus experience from across the healthcare sector. The Tool uses a model based on data from individuals who had been hospitalised and/or who had died during the first wave of coronavirus (Spring 2020). The data was compiled not only from hospital records, but from general practices (GPs) to reflect the impact on local communities. This also means that the model is more representative of the coronavirus risk to population as a whole and not as would be if only hospitalised data were used.  To develop the Tool, Oxford University analysed this data to identify some key factors that might mean people could be at greater risk if they contracted coronavirus.  Factors such as age, body mass index, ethnicity, certain health conditions and the level of deprivation in the area they live were identified as key factors that might mean a person is at greater risk. Oxford developed a model which weighted each of these factors and these weightings are used within the Tool to produce the risk assessment results from the information entered by the clinician. The model will evolve over time as more information regarding the risks of coronavirus is obtained.  The British Medical Journal has published a paper for peer review (<https://www.bmj.com/content/371/bmj.m3731>) which explains the data used in the model. From this paper, it is expected that clinicians would gain an understanding of the more significant factors that increase the risk to patients if they contract coronavirus, and would be able to discuss these with their patients in the context of the risk assessment results produced. The use of the Tool means that risk assessment results are produced that most accurately reflect the coronavirus risk specific to the patient based on the information provided at that point in time and enables personalised discussion to take place with the clinicians in light of their risk assessment results, with relevant health advice being provided.  Over time, the healthcare organisation will understand further whether the benefits to it and its patients of the Tool are as significant as expected, but the breadth of information through the Tool is greater than available from the healthcare organisation’s own resources currently.  **Is there another way to achieve the same outcome?**  It is considered that there is no other way readily available to achieve this without utilising the Tool. As discussed above, while clinicians can gain some understanding of significant risk factors from reviewing the British Medical Journal paper, it is only by utilising the Tool itself that personalised risk assessments are made available for direct care of the patient and for a consultation with a patient.  In any event, the Tool itself does not process any personal data as it does not collect any data that directly or indirectly identifies the patient.  **How will you prevent function creep?**  The Tool is intended for use by the clinician in a direct care consultation with their patient, in preparation for a consultation or for other relevant direct care purposes. It will not be used by the clinician for any other purpose. The conditions of use for the Tool make this expressly clear. Should other purposes be identified for use of the Tool by clinicians, these would be considered under a separate DPIA and in conjunction with NHS Digital as the provider of the service.  **How will you ensure data quality and data minimisation?**  Data processed by the Tool shall be provided by the patient, obtained in the consultation with the clinician or taken from the current patient record held by the healthcare organisation. The patient may be present when the data is input into the Tool and, in such instances, shall be able to correct any inaccuracies that they are aware of.  Patient records are revised and updated by new or up-to-date information as appropriate in subsequent consultations.  No personal data is processed by the Tool.  The only personal data processed by the health care professional is the data which is required by the Tool which are necessary for the purposes of deriving risk assessment results for the patient as approved as a medical device by MHRA.  **What information will you give individuals?**  When present, patients shall see the inputs to the Tool and the risk assessment results derived from it during the consultation. The clinician shall then have a clinical conversation with the patient around the coronavirus risks to them and what actions they might consider to mitigate the risks where appropriate. In other instances, where the clinician inputs data into the Tool in the absence of the patient, they are able to use the outputs in consultation with the patient where they consider that appropriate for direct care of the patient.  A template Privacy Notice has been supplied by NHS Digital which can be provided to the patient by the clinician which explains how the patient’s personal data is processed by the healthcare organisation for the purposes of the Tool application.  **How will you help to support their rights?**  The healthcare organisation can provide the patient with a Privacy Notice which supplements the organisation’s main Privacy Notice which is also available online.  The clinician will explain in plain English how the risk assessment results are derived and that the Tool itself will evolve as more knowledge is gained about coronavirus risks through summarising the information about the workings of Tool and the Tool is updated.  The Tool is used during a consultation a patient and otherwise to support direct care of patients.  **What measures do you take to ensure processors comply?**  No data processors are involved. This is a consultation between the clinician and their patient only or otherwise for use by a clinician for direct care purposes only.  **How do you safeguard any international transfers?**  Not applicable for the purposes of the use of the Tool for direct care purposes including consultation with patients.  **Healthcare Organisation Necessity and Proportionality Assessment**  Special category data is processed for the purposes of obtaining risk assessment results from the Tool and for purposes of consultation with the patient. It is considered that this is proportionate and necessary because:   * This is for a direct care purpose; * It is considered necessary to enable a richer conversation about coronavirus risk with patients than would otherwise be possible; * Coronavirus risk is material for large sections of the population; and * Personal data is not transferred outside of the Healthcare organisation through use of the Tool.   .  **Healthcare Organisation lawful basis for processing**  The healthcare organisation will rely upon the following legal basis to collect and process personal data in through the Tool for direct care purposes only, including where appropriate in consultation with patients and in the recording of the risk assessment results on patients records:  Personal Data  GDPR  Article 6 (1)(e) – Public Task (direct healthcare)  Special Category Data (Health and Ethnicity)  GDPR  Article 9 (2) (h) – Purposes of preventative or occupational medicine for healthcare data.  Data Protection Act 2018  Schedule 1, Paragraph 2 Health or social care purposes.  Duty of Confidence  The healthcare organisation is processing the personal data in order to answer the questions in the Tool and to record the risk assessment results in their patient health record. This is for direct care purposes to provide patients with safe care and treatment and would be within the reasonable expectations of the patient for the purposes of providing that direct care.  **Patient Opt Out Preferences**  If a health organisation stores personal data on their own system as Controller, then they will need to abide by the patient’s opt out preferences in relation to any subsequent processing the personal data where this applies. |

# Step 5: Identify and assess risks

|  |  |  |  |
| --- | --- | --- | --- |
| **Describe source of risk and nature of potential impact on individuals.** Include associated compliance and corporate risksas necessary. | **Likelihood of harm**  Remote, possible or probable  **Before mitigation identified at Step 6** | **Severity of harm**  Minimal, significant or severe  **Before mitigation identified at Step 6** | **Overall risk**  Low, medium or high  **Before mitigation identified at Step 6** |
| 1. Patient does not understand how the Tool is processing their personal data 2. Patient does not understand what the risk assessment results means to them 3. The Tool is defective and produces a risk assessment results that are inaccurate and do not accurately represent the risk of coronavirus to the patient. 4. As the risk assessment is based upon historic coronavirus outcomes for the period February to June 2020 there is a risk that the risk assessment result produced by the Tool may be inaccurate because social and other factors during validation period may be different to those factors at the current time. 5. The use of the Tool constitutes solely automated decision making. 6. The patient does not understand how the Tool works or how their risk assessment results are generated. | Possible  Probable  Possible  Possible  Remote  Probable | Significant  Severe  Severe  Severe  Severe  Severe | Medium  High  High  High  Medium  High |

# Step 6: Identify measures to reduce risk

| **Identify additional measures you could take to reduce or eliminate risks identified as medium or high risk in step 5** | | | | |
| --- | --- | --- | --- | --- |
| **Risk** | **Options to reduce or eliminate risk** | **Effect on risk**  Eliminated Reduced Accepted | **Residual risk**  Low Medium High | **Measure approved**  Yes/No |
| 1. Patient does not understand how the Tool is processing their personal data | The Tool does not process personal data. Only the clinician can identify the patient and only the clinician is processing personal data about the patient.  The Privacy Notice sets out that no personal data is processed by the Tool and the clinician will explain to the patient what data is being put into the Tool when it is used during a consultation with a patient or where a consultation with a patient is considered appropriate by the clinician following use of the Tool by them. | Reduced | Low | Yes |
| 2. Patient does not understand what the risk assessment results mean to them | The COVID-19 Clinical Risk Assessment Tool is only used for direct care purposes.  Clinicians are provided with detailed information about the Tool including the link to the British Medical Journal article on the risk prediction model which is the QCovid® model underpinning the Tool  Clinicians are provided with guidance notes about the Tool and how to explain the risk assessment results to patients. | Reduced | Low | Yes |

| 3. The Tool is defective and produces risk assessment results that are inaccurate and do not accurately represent the risk of coronavirus to the patient | The Tool has been approved by the MHRA for use as a medical device within class 1. Class 1 contains medical devices that have a low to moderate risk to the patient or user. The CE mark is a logo that indicates the service meets legislation relating to safety and performance.  The underlying QCovid® model was commissioned by the Chief Medical Officer and the underlying research published in the [BMJ](https://www.bmj.com/content/371/bmj.m3731) for peer review.  The Tool has been subject to clinical engagement and assessment. The underlying QCovid® model has been evaluated to ascertain whether it discriminated effectively on the two primary outcomes (catching and hospitalisation or catching and death). It showed good statistical discrimination in determining a patient’s risk of hospitalisation or death from coronavirus and the statistical methods are described in the BMJ paper. NHS Digital has invited feedback on the COVID-19 Clinical Risk Assessment Tool from clinicians.  The COVID-19 Clinical Risk Assessment Tool was presented to NHS Digital’s Clinical Safety Group for Clinical Authority to Release.  The research team at Oxford University have provided example data sets containing 2 million example patients with risk outcomes which has been used to verify the implementation.  The research protocol followed by Oxford University has been published and can be accessed via <https://www.bmj.com/content/371/bmj.m3731>. Peer review was provided on publication. | Reduced | Low | Yes |
| --- | --- | --- | --- | --- |
| 4. Being based upon historic coronavirus outcomes for the period February to June 2020 (the validation period) the risks to patients provided with risk assessment results from the Tool by their clinician may be inaccurate because social and other factors during validation period may be different to those factors at the current time. | Guidance for clinicians makes clear that the Tool is only made available for direct care purposes and, where appropriate in the clinician’s clinical judgement, to facilitate individualised discussions between clinically trained professionals and patients about coronavirus risk. This will enable shared decision making, allowing patients to understand their risk and discuss actions that could be taken in the context of other important factors including local prevalence, risk appetite, occupation and personal circumstances. Clinical conversations could include advice to shield to limit the risks of catching the virus, health promotion opportunities (such as losing weight) to reduce the risk of serious illness if infected, and coronavirus risk mitigation in the workplace. Therefore, whilst the Tool is likely to evolve and become more accurate in assessing coronavirus risk to patients, the limitation on its use to the clinical consultation with clinicians provided with guidance notes on its use greatly mitigates the risk of serious consequences of any inaccuracy in risk assessment results.  The underlying risk model will be updated periodically as new evidence becomes available and this will, in turn, result in changes to the Tool and the guidance to clinicians accompanying it.  The underlying model uses a default BMI of 25 if no BMI is entered. If the BMI is over 47 the Tool will use a BMI of 47, and if the BMI is under 15 the Tool will use 15. As BMI is an important and modifiable risk factor, clinicians are encouraged to complete the height and weight fields when using the Tool. To further reduce the risk of default values being used, the guidance for clinicians explains how the Tool is to be used in the context of a clinical consultation with the patient. Clinicians are also encouraged to review the BMJ paper to consider the relative significance of BMI and other factors contributing to the risk assessment for the purposes of their consultation with patients.  The patient shall only receive the risk assessment results in the context of a clinical consultation and therefore their particular circumstances can be considered in that consultation.  One of the caveats of the risk assessment set out in guidance to the clinicians is that it should only be used with care and with clinical judgement to remove people from the Shielded Patient List (SPL), when people are added to the SPL by their clinician using the CEV criteria set out by the CMO, and as a joint decision with their patient. This is because it may underestimate the risk for anyone who is on the SPL. It is also explained in the patient Privacy Notice. | Reduced | Low | Yes |
| 5. The model constitutes solely automated decision making | Guidance to clinicians on use of the Tool makes clear that the Tool does not make a clinical assessment but provides a factor for consideration by the clinician with their patient on the most appropriate healthcare arrangements for the patient.  No decision is taken solely on the basis of the risk assessment results which are provided to enable a rich conversation about coronavirus risk between a patient and their clinician or otherwise for the clinician to aid them in their understanding of coronavirus risk to their patients for their direct care. | Reduced | Low | Yes |
| 6. The patient does not understand how the Tool works or how their risk assessment result is generated | Clinical guidance provided to clinicians explains the how the Tool works and provides explanation as to how their risk assessment results are generated. The British Medical Journal has published a paper for peer review (<https://www.bmj.com/content/371/bmj.m3731>) which explains the data used in the underlying QCovid® model has also been included in the guidance to provide further details for the clinician.  NHS Digital has provided a Privacy Notice for healthcare organisations to provide to patients. | Reduced | Low | Yes |

# Step 7: Sign off and record outcomes

|  |  |  |
| --- | --- | --- |
| **Item** | **Name/position/date** | **Notes** |
| Measures approved by: |  | Integrate actions back into project plan, with date and responsibility for completion |
| Residual risks approved by: |  | If accepting any residual high risk, consult the ICO before going ahead |
| DPO advice provided: |  | DPO should advise on compliance, step 6 measures and whether processing can proceed |
| Summary of DPO advice: | | |
| DPO advice accepted or overruled by: |  | If overruled, you must explain your reasons |
| Comments: | | |
| Consultation responses reviewed by: |  | If your decision departs from individuals’ views, you must explain your reasons |
| Comments: | | |
| This DPIA will kept under review by: |  | The DPO should also review ongoing compliance with DPIA |